Download PDFPDF

P03.03 Novel machine-learning tools improve cost-effective development of personalised immunotherapies: lowering false positive rates in the search for actionable immunogenic neoantigens
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address